Mark Massaro

Contact Us

Mark Massaro is a Managing Director and BTIG Life Science and Diagnostic Tools Analyst. Prior to BTIG, he served as the Chief Financial Officer at ArcherDX, Inc., an oncology diagnostics and pharmaceutical services company, which was acquired by Invitae Corporation. Previously, Mr. Massaro was a Managing Director and Senior Equity Research Analyst within Diagnostics and Life Science Tools at Canaccord Genuity, where he spent more than eight years focused on high-growth, precision medicine and next-generation sequencing companies, as well as molecular and point-of-care diagnostics, reference labs and animal health. He was named a “Rising Star” in Institutional Investor’s All America Survey for life science and diagnostics tools in October 2016. Earlier in his career, Mr. Massaro was an Associate Equity Analyst within Healthcare Services at Avondale Partners and held corporate finance and financial reporting roles at Dell EMC and Fidelity Investments. He earned an MBA from Babson College and a BA in economics and Spanish from the University of Massachusetts – Amherst.


Coverage Area

Company Ticker
Adaptive Biotechnologies ADPT
Exact Sciences Corporation EXAS
NeoGenomics, Inc. NEO
Cerus Corporation CERS
Castle Biosciences, Inc. CSTL
Guardant Health GH
Natera, Inc. NTRA
Exagen Inc. XGN
Personalis, Inc. PSNL
Oncocyte Corporation OCX
DermTech DMTK
Bionano Genomics BNGO
Alpha Teknova TKNO
MaxCyte, Inc. MXCT
GeneDx WGS
Ginkgo Bioworks DNA
Cue Health HLTH
Lucid Diagnostics LUCD
MDx Health MDXH
Renalytix RNLX
Akoya Biosciences AKYA
SOPHiA Genetics SOPH